|
|
 Previous Article | Table of Contents | Next Article 
Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after
dormancy is established
ES Vitetta, TF Tucker, E Racila, YW Huang, R Marches, N Lane, RH Scheuermann, NE Street, T Watanabe and JW Uhr
Cancer Immunobiology Center and Department of Microbiology, University of
Texas Southwestern Medical Center at Dallas, 75235, USA.
The majority of BALB/c mice immunized with the BCL1 lymphoma-derived
idiotype (Id+) IgM and subsequently challenged with BCL1 tumor cells
develop a state of tumor dormancy. The vast majority of dormant lymphoma
cells are in cell cycle arrest, but there are also residual replicating
cells. In the present studies, we attempted to define features of both the
dormant lymphoma cells and the host that lead to escape from dormancy.
Escape from dormancy occurs at a steady rate over a 2-year period,
suggesting that it is a stochastic process. We found that, in the majority
of mice, escape was due to the emergence of genetic variants that were no
longer susceptible to the anti-Id- mediated induction of dormancy. Ten
percent of these variants were Id-; the remainder were Id+ but could grow
in the presence of anti-Id antibodies, suggesting that there were mutations
in molecules involved in one or more mIg-mediated negative-signaling
pathways. In two of five such escapees, alterations in either Syk, HS1,
and/or Lyn were observed. In a small percentage of mice, a low titer of
circulating anti-Id antibody before tumor challenge correlated with a
subsequent, more rapid loss of dormancy.
Volume 89,
Issue 12,
pp. 4425-4436,
06/15/1997
Copyright © 1997 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Stefanello, S. Romussi, P. Signorelli, M. Caniatti, M. DiGiancamillo, P. Roccabianca, and G. Avallone
Primary Osseous Melanoma in the Tibia of a Dog
J. Am. Anim. Hosp. Assoc.,
May 1, 2008;
44(3):
139 - 143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saudemont, A. Hamrouni, P. Marchetti, J. Liu, N. Jouy, D. Hetuin, F. Colucci, and B. Quesnel
Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1
Cancer Res.,
May 1, 2007;
67(9):
4491 - 4498.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Meng, D. Tripathy, E. P. Frenkel, S. Shete, E. Z. Naftalis, J. F. Huth, P. D. Beitsch, M. Leitch, S. Hoover, D. Euhus, et al.
Circulating Tumor Cells in Patients with Breast Cancer Dormancy
Clin. Cancer Res.,
December 15, 2004;
10(24):
8152 - 8162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saudemont and B. Quesnel
In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis
Blood,
October 1, 2004;
104(7):
2124 - 2133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rinaldi, F. Ria, P. Parrella, E. Signori, A. Serra, S. A. Ciafrè, I. Vespignani, M. Lazzari, M. G. Farace, G. Saglio, et al.
Antibodies Elicited by Naked DNA Vaccination against the Complementary-determining Region 3 Hypervariable Region of Immunoglobulin Heavy Chain Idiotypic Determinants of B-lymphoproliferative Disorders Specifically React with Patients' Tumor Cells
Cancer Res.,
February 1, 2001;
61(4):
1555 - 1562.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. J. Dobrzanski, J. B. Reome, and R. W. Dutton
Type 1 and Type 2 CD8+ Effector T Cell Subpopulations Promote Long-Term Tumor Immunity and Protection to Progressively Growing Tumor
J. Immunol.,
January 15, 2000;
164(2):
916 - 925.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Farrar, K. H. Katz, J. Windsor, G. Thrush, R. H. Scheuermann, J. W. Uhr, and N. E. Street
Cancer Dormancy. VII. A Regulatory Role for CD8+ T Cells and IFN-{gamma} in Establishing and Maintaining the Tumor-Dormant State
J. Immunol.,
March 1, 1999;
162(5):
2842 - 2849.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Tutt, R. R. French, T. M. Illidge, J. Honeychurch, H. M. McBride, C. A. Penfold, D. T. Fearon, R. M. E. Parkhouse, G. G. B. Klaus, and M. J. Glennie
Monoclonal Antibody Therapy of B Cell Lymphoma: Signaling Activity on Tumor Cells Appears More Important Than Recruitment of Effectors
J. Immunol.,
September 15, 1998;
161(6):
3176 - 3185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Davis, D. G. Maloney, D. K. Czerwinski, T.-M. Liles, and R. Levy
Anti-Idiotype Antibodies Can Induce Long-Term Complete Remissions in Non-Hodgkin's Lymphoma Without Eradicating the Malignant Clone
Blood,
August 15, 1998;
92(4):
1184 - 1190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. De Jonge, C. Heirman, M. d. Veerman, S. Van Meirvenne, M. Moser, O. Leo, and K. Thielemans
In Vivo Retargeting of T Cell Effector Function by Recombinant Bispecific Single Chain Fv (Anti-CD3 Anti-Idiotype) Induces Long-Term Survival in the Murine BCL1 Lymphoma Model
J. Immunol.,
August 1, 1998;
161(3):
1454 - 1461.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Racila, D. Euhus, A. J. Weiss, C. Rao, J. McConnell, L. W. M. M. Terstappen, and J. W. Uhr
Detection and characterization of carcinoma cells in the blood
PNAS,
April 14, 1998;
95(8):
4589 - 4594.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
